How Do I Choose An Expression System For My Biotherapeutic Molecule?

Choosing the right expression system is a pivotal early decision in biotherapeutic development, and the optimal approach depends heavily on the complexity and characteristics of the molecule. In this video, Peter O'Callaghan, Senior Director and Head of Expression System Sciences, Licensing, explains how developers can approach this decision and match a molecule to the appropriate expression platform.

The discussion explores how simpler proteins that don't require complex glycosylation can often be produced in microbial systems such as E. coli, offering shorter fermentation times and rapid generation of high titers. For molecules with greater complexity but limited glycosylation needs, Pichia can provide an intermediate option between microbial and mammalian systems. And for the most complex molecules — including monoclonal antibodies with multiple disulfide bridges and complex N-glycans — O'Callaghan discusses the role of Lonza's CHO-based mammalian platform and its GS Gene Expression System®.

The video also highlights the flexibility available to developers, whether they access expression technologies through licensing for use in their own facilities or draw on Lonza's global services network.

Watch the full video to learn how molecule complexity can guide expression system selection, from early discovery through commercial supply.